Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3912295 | 0.82 | PTPN1 (0.41) | PTPN1GAAL3MBTL1KMT2AMAPT | |
| SCHEMBL3906569 | 0.82 | ALDH1A1 (0.49) | PTPN1GAAL3MBTL1KMT2AMAPT | |
| SCHEMBL13867918 | 0.79 | PTPN1 (0.54) | PTPN1GAAL3MBTL1KMT2AMAPT | |
| SCHEMBL3906716 | 0.79 | PTPN1 (0.71) | PTPN1KMT2AMAPTHSD17B10TSHR | |
| SCHEMBL3908251 | 0.79 | PTPN1 (0.48) | PTPN1GAAL3MBTL1KMT2AMAPT | |
| SCHEMBL3907240 | 0.76 | PTPN1 (0.45) | PTPN1GAAL3MBTL1KMT2AMAPT | |
| SCHEMBL3911917 | 0.75 | PTPN1 (0.49) | PTPN1GAAL3MBTL1KMT2AMAPT | |
| SCHEMBL3909688 | 0.72 | PTPN1 (0.46) | PTPN1GAAL3MBTL1KMT2AMAPT | |
| SCHEMBL6278144 | 0.72 | PTPN1 (0.46) | PTPN1GAAL3MBTL1KMT2AMAPT | |
| SCHEMBL6266995 | 0.71 | PTPN1 (0.45) | PTPN1GAAL3MBTL1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521473-B2 | Inhibitors of protein tyrosine phosphatase 1B | WYETH (US) | 2009-04-21 | — | — | US | disclosed |
| US-20050203087-A1 | Inhibitors of protein tyrosine phosphatase 1B | WYETH | 2005-09-15 | — | — | US | disclosed |
| WO-2005081954-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203087-A1 | Inhibitors of protein tyrosine phosphatase 1B | PTPRO, PTPRS, PTPRM | PTPN1 11/4885GAA 920/4885L3MBTL1 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.